title: A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients.
abstract: Maraviroc is the first commercialized CCR5 inhibitor for HIV therapy. A new high-performance liquid chromatography-ultraviolet method to quantify maraviroc concentrations in human plasma was developed and validated. The method is based on a protein precipitation procedure, with an acidic solution of acetonitrile (trifluoroacetic acid 0.1%) and quinoxaline as internal standard. The analytes were eluted using a gradient run in 15 minutes on an analytical C18 Luna column (150 mm x 4.6 mm ID) with a particle size of 5 mum. Maraviroc and internal standard were detected by UV at 193 nm and 352 nm, respectively. The calibration curve was linear up to 2500 ng/mL. The mean recovery of maraviroc was 96%. All validation data were in accordance with U.S. Food and Drug Administration requirements. The new high-performance liquid chromatography-ultraviolet method reported here could be used routinely to monitor plasma concentrations of maraviroc in healthy volunteers and HIV-infected patients.
authors.affiliation: Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Turin, Italy. antonio.davolio@unito.it
authors.forename: Antonio
authors.initials: A
authors.lastname: D'Avolio
authors.forename: Marco
authors.initials: M
authors.lastname: Simiele
authors.forename: Lorena
authors.initials: L
authors.lastname: Baietto
authors.forename: Marco
authors.initials: M
authors.lastname: Siccardi
authors.forename: Mauro
authors.initials: M
authors.lastname: Sciandra
authors.forename: Samantha
authors.initials: S
authors.lastname: Patanella
authors.forename: Stefano
authors.initials: S
authors.lastname: Bonora
authors.forename: Giovanni
authors.initials: G
authors.lastname: Di Perri
mesh_terms: D065100:CCR5 Receptor Antagonists; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D003510:Cyclohexanes / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016903:Drug Monitoring / Q000379:methods; D023581:HIV Fusion Inhibitors / Q000493:pharmacokinetics* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D000077592:Maraviroc; D015203:Reproducibility of Results; D014230:Triazoles / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D014230:Triazoles; D000077592:Maraviroc